Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Keros Therapeutics Inc

Healthcare US KROS

10.77USD
0.27(2.57%)

Last update at 2026-06-04T20:00:00Z

Day Range

10.5910.89
LowHigh

52 Week Range

27.0273.00
LowHigh

Fundamentals

  • Previous Close 10.50
  • Market Cap1759.09M
  • Volume155863
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-178.63000M
  • Revenue TTM0.23M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM -87.26500M
  • Diluted EPS TTM-5.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -104.67900M -56.73300M -45.53300M -12.33600M -1.07800M
Minority interest - - - - -
Net income -104.68000M -58.74400M -45.36100M -12.34400M -1.33500M
Selling general administrative 27.52M 21.33M 12.80M 3.18M 1.58M
Selling and marketing expenses - - - - -
Gross profit - 20.10M - 10.00M 10.00M
Reconciled depreciation 0.67M 0.38M 0.28M 0.21M 0.15M
Ebit -114.79000M -56.37300M -46.65700M -10.56300M -1.32100M
Ebitda -104.67800M -56.72900M -45.52700M -9.79700M -1.16800M
Depreciation and amortization 10.11M -0.35600M 1.13M 0.77M 0.15M
Non operating income net other 10.11M -0.35600M 1.13M - -
Operating income -114.79000M -56.37300M -46.65700M -10.56300M -1.69100M
Other operating expenses 107.71M 76.47M 44.20M 20.00M 11.32M
Interest expense 0.00100M 0.00400M 0.00600M 0.00800M 0.00600M
Tax provision 0.00000M 2.01M -0.17200M 0.00000M 0.26M
Interest income - - - 2.57M 0.04M
Net interest income -0.00100M -0.00400M -0.00600M -0.00800M 0.00600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00100M 2.01M -0.17200M 0.00800M 0.26M
Total revenue 0.00000M 20.10M 0.00000M 10.00M 10.00M
Total operating expenses 107.71M 76.47M 44.20M 20.00M 11.32M
Cost of revenue - - - - -
Total other income expense net 10.11M -0.36000M 1.12M -1.77300M 0.24M
Discontinued operations - - - - -
Net income from continuing ops -104.67900M -58.74400M -45.36100M -12.33600M -1.33500M
Net income applicable to common shares -104.67900M -58.74400M -45.36100M -14.13600M -2.34600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 370.02M 306.78M 255.25M 269.44M 10.96M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.00M 6.72M 0.34M 0.16M 0.23M
Total liab 37.81M 29.36M 12.08M 7.72M 5.50M
Total stockholder equity 332.21M 277.42M 243.17M 261.72M 5.45M
Deferred long term liab - 0.40M - - -
Other current liab 0.67M 12.75M 0.20M 0.22M 0.11M
Common stock 0.00300M 0.00200M 0.00200M 0.00200M 0.00200M
Capital stock 0.00300M 0.00200M 0.00200M 0.00200M 0.00200M
Retained earnings -381.42600M -228.43400M -123.75500M -65.01100M -19.65000M
Other liab - - - 0.06M 0.12M
Good will - - - - -
Other assets - 3.44M 1.41M 0.99M 0.12M
Cash 331.15M 279.05M 230.04M 265.88M 7.02M
Cash and equivalents - - - - -
Total current liabilities 24.37M 16.55M 11.85M 7.18M 4.49M
Current deferred revenue 17.25M - 7.13M 4.39M 1.92M
Net debt -316.70300M -265.78200M -228.94900M -264.97700M -5.74500M
Short term debt 1.00M 0.46M 0.86M 0.42M 0.38M
Short long term debt - - - - -
Short long term debt total 14.44M 13.27M 1.09M 0.90M 1.27M
Other stockholder equity 713.64M 505.86M 366.93M 326.73M 25.10M
Property plant equipment - 2.02M 1.33M 1.60M 1.91M
Total current assets 347.29M 285.77M 251.44M 267.73M 8.93M
Long term investments - - - - -
Net tangible assets - 277.42M 243.17M 261.72M -19.44600M
Short term investments - - - - -
Net receivables 1.09M 0.84M 18.00M 0.22M 0.92M
Long term debt - - - - 4.96M
Inventory 14.05M -0.84100M 3.06M - 0.76M
Accounts payable 5.45M 3.34M 3.65M 2.15M 2.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - -269.44300M -0.45300M
Additional paid in capital - - - - -
Common stock total equity - 0.00200M 0.00200M 0.00200M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -228.43400M -123.75500M -65.01100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.05M 3.44M 1.41M 0.12M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 22.73M 21.01M 3.81M 1.72M 2.03M
Capital lease obligations 14.44M 13.27M 1.09M 0.90M 1.27M
Long term debt total - - - - 4.96M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.24100M -1.02400M -0.29400M -0.27100M -0.21700M
Change to liabilities 4.91M 4.08M 0.06M -8.68800M -10.00200M
Total cashflows from investing activities -1.24100M -1.02400M -0.29400M -0.27100M -0.21700M
Net borrowings - - -0.42000M - -
Total cash from financing activities 120.31M 28.55M 296.04M 0.01M 11.46M
Change to operating activities -3.28400M 0.45M 2.21M 1.96M 17.95M
Net income -104.67900M -58.74400M -45.36100M -12.33600M -1.33500M
Change in cash 49.01M -34.62200M 258.86M -16.25500M 18.29M
Begin period cash flow 231.37M 265.99M 7.13M 23.39M 5.10M
End period cash flow 280.38M 231.37M 265.99M 7.13M 23.39M
Total cash from operating activities -70.06200M -62.14800M -36.89400M -15.99800M 7.04M
Issuance of capital stock 119.58M 28.17M 299.20M 0.00000M 11.50M
Depreciation 0.67M 0.38M 0.28M 0.21M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 1.04M - - -
Change to account receivables 18.00M -18.00000M 0.92M -18.00000M -18.00000M
Sale purchase of stock 120.31M 28.55M 299.01M 0.01M 11.51M
Other cashflows from financing activities 0.73M 0.38M 52.84M -0.27100M 11.46M
Change to netincome 18.69M 11.77M 5.91M 2.85M 0.28M
Capital expenditures 1.24M 1.02M 0.29M 0.27M 0.22M
Change receivables 18.00M -18.00000M - - -
Cash flows other operating -7.66500M -1.62500M 1.50M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 49.01M -34.62200M 258.86M - -
Change in working capital 14.31M -16.07000M 2.27M -6.72400M 7.95M
Stock based compensation 18.68M 11.72M 4.10M 0.06M 0.08M
Other non cash items 0.95M 0.52M 1.82M 2.79M 0.19M
Free cash flow -71.30300M -63.17200M -37.18800M -16.26900M 6.83M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KROS
Keros Therapeutics Inc		 0.27 2.57% 10.77 - - 13966.49 6.36 11890.58 -11.7986
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics Inc

1050 Waltham Street, Lexington, MA, United States, 02421

Key Executives

Name Title Year Born
Dr. Jasbir S. Seehra Ph.D. Pres, CEO, Treasurer, & Director 1956
Mr. Keith C. Regnante MBA Chief Financial Officer 1970
Dr. Jennifer Lachey Ph.D. Chief Scientific Officer 1973
Mr. Christopher Rovaldi M.Sc. Chief Operating Officer 1974
Ms. Esther Cho J.D. Head of Legal & Corp. Sec. NA
Ms. Robin Wagner VP of HR NA
Dr. Simon Cooper MBBS Chief Medical Officer 1970
Dr. Jasbir S. Seehra Ph.D. President, CEO, Treasurer, & Director 1956
Mr. Christopher Rovaldi M.Sc. Chief Operating Officer 1975
Ms. Esther Cho J.D. Senior VP, General Counsel & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions